Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer
Amir Noeparast(Vrije Universiteit Brussel), Jacques De Grève(Vrije Universiteit Brussel)
Cited by 31
Related Papers
miR-146a Inhibits Cell Growth, Cell Migration and Induces Apoptosis in Non-Small Cell Lung Cancer Cells
|PLoS ONE|2013|267
Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab
|BMC Medicine|2012|131
Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib
|Oncotarget|2016|100
Synergistic Effect of Afatinib with Su11274 in Non-Small Cell Lung Cancer Cells Resistant to Gefitinib or Erlotinib
|PLoS ONE|2013|51
Influence of RT-qPCR primer position on EGFR interference efficacy in lung cancer cells
|Biological Procedures Online|2010|46